Local photodynamic therapy with Zn(II)-phthalocyanine in an experimental model of intimal hyperplasia.
Photodynamic therapy (PDT) appears to be a novel promising modality to prevent intimal hyperplasia (IH) and restenosis after angioplasty. Local PDT, that consists of local delivery of photosensitizing agents followed by intraluminal local irradiation, represents a recent advancement. This methodology requires optimization in order to achieve the best prompt outcome especially in terms of pharmacokinetics of the photosensitizing agent. We studied the pharmacokinetic properties by using the photosensitizing agent Zn(II)-phthalocyanine (ZnPc), locally released by a channeled balloon. The efficacy of local PDT in reducing IH was evaluated in an experimental rabbit model of arterial injury. The maximum accumulation of ZnPc was found at 30 min: the injured portion of the artery gave a ZnPc recovery of 1.18 micromol/mg, as compared with undetectable amounts of ZnPc in the non injured arteries; within 90 min after the local delivery, clearance of the agent was almost complete. Local PDT produced an effective reduction of IH in our vascular injury model: at 7, 14, 21 and 28 days IH and intima/media ratio (IMR) was significantly reduced as compared with balloon injured arteries. The local delivery of ZnPc showed favourable pharmacokinetic properties, that allow the performance of PDT immediately after the vascular injury. Local PDT performed in these conditions represents a promising approach to prevent IH after balloon injury. Further studies are needed to better clarify the biological response of the injured arterial wall to local PDT.
Visonà
A
A
Department of Internal Medicine, University of Padua, Italy. cumei1@ulssasolo.ven.it
Angelini
A
A
Gobbo
S
S
Bonanome
A
A
Thiene
G
G
Pagnan
A
A
Tonello
D
D
Bonandini
E
E
Jori
G
G
D000818:Animals; D004195:Disease Models, Animal; D005263:Femoral Artery / Q000293:injuries* / Q000473:pathology; D006965:Hyperplasia / Q000188:drug therapy; D007083:Iliac Artery / Q000293:injuries* / Q000473:pathology; D007211:Indoles / Q000493:pharmacokinetics / Q000627:therapeutic use*; D054833:Isoindoles; D008297:Male; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011817:Rabbits; D017967:Zinc Compounds
D007211:Indoles; D054833:Isoindoles; D009942:Organometallic Compounds; D017319:Photosensitizing Agents; D017967:Zinc Compounds; C052159:Zn(II)-phthalocyanine